Discovery and lead identification of quinazoline-based BRD4 inhibitors

  • Bioorg Med Chem Lett. 2018 Nov 15;28(21):3483-3488. doi: 10.1016/j.bmcl.2018.08.039.
Shyh-Ming Yang  1 ,  Daniel J Urban  2 ,  Makoto Yoshioka  3 ,  Jeffrey W Strovel  3 ,  Steven Fletcher  4 ,  Amy Q Wang  2 ,  Xin Xu  2 ,  Pranav Shah  2 ,  Xin Hu  2 ,  Matthew D Hall  2 ,  Ajit Jadhav  2 ,  David J Maloney  5
Affiliations
  • 1. National Center for Advancing Translational Sciences, National Institutes of Health, 9800 Medical Center Drive, Rockville, MD 20850, United States. Electronic address: [email protected].
  • 2. National Center for Advancing Translational Sciences, National Institutes of Health, 9800 Medical Center Drive, Rockville, MD 20850, United States.
  • 3. ConverGene LLC., 3093 Beverly Lane, Unit C, Cambridge, MD 21613, United States.
  • 4. Department of Pharmaceutical Sciences, University of Maryland School of Pharmacy, 20 North Pine Street, Baltimore, MD 21201, United States.
  • 5. National Center for Advancing Translational Sciences, National Institutes of Health, 9800 Medical Center Drive, Rockville, MD 20850, United States. Electronic address: [email protected].
PMID: 30268702 DOI: 10.1016/j.bmcl.2018.08.039
Abstract

A new series of quinazoline-based analogs as potent bromodomain-containing protein 4 (BRD4) inhibitors is described. The structure-activity relationships on 2- and 4-position of quinazoline ring, and the substitution at 6-position that mimic the acetylated lysine are discussed. A co-crystallized structure of 48 (CN750) with BRD4 (BD1) including key inhibitor-protein interactions is also highlighted. Together with preliminary rodent pharmacokinetic results, a new lead (65, CN427) is identified which is suitable for further lead optimization.

Keywords
BET inhibitor; BRD4; Bromodomain; Cancer; Inflammation; Quinazoline.
Products